Technical Analysis for ARQL - ArQule, Inc.

Grade Last Price % Change Price Change
grade A 6.78 -3.56% -0.25
ARQL closed down 3.56 percent on Friday, May 17, 2019, on 1.33 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ARQL trend table...

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish 0.00%
Jack-in-the-Box Bullish Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Inside Day Range Contraction 0.00%
BB Squeeze Ended Range Expansion 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Support Bullish -3.56%
New 52 Week Closing High Bullish -3.56%
Expansion Breakout Bullish Swing Setup -3.56%
Pocket Pivot Bullish Swing Setup -3.56%

Older signals for ARQL ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product candidate tivantinib is an inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase 3 clinical trial for the treatment of non-small cell lung and liver cancer; and Phase 2 clinical trial for the treatment of colorectal cancer. The company is also involved in the development of ARQ 087, an inhibitor of fibroblast growth factor receptor; ARQ 621, an inhibitor of the Eg5 kinesin motor protein; and ARQ 736, an inhibitor of the RAF kinases, which are in Phase 1 clinical development, as well as ARQ 761, an activator of the E2F-1 damage response/checkpoint pathway. It has partnership agreement with Daiichi Sankyo Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. for implementing a clinical development program designed to realize the broad potential of tivantinib as a single agent; and in combination with other anti-cancer therapies in various disease indications. In addition, the company has research collaboration with Daiichi Sankyo Co., Ltd. to discover selective inhibitors of two kinases in the field of oncology based on its ArQule Kinase Inhibitor Platform (AKIP) technology. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.
Chemistry Biotechnology Cancer Disease Organic Chemistry Colorectal Cancer Cancer Therapies Ethers Cancer Therapeutics Tyrosine Kinase Inhibitors Kinase Tyrosine Kinase C Met Treatment Of Colorectal Cancer
Is ARQL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 7.21
52 Week Low 2.23
Average Volume 1,410,822
200-Day Moving Average 4.6034
50-Day Moving Average 5.646
20-Day Moving Average 6.324
10-Day Moving Average 6.363
Average True Range 0.3916
ADX 37.81
+DI 29.2558
-DI 10.1399
Chandelier Exit (Long, 3 ATRs ) 5.8752
Chandelier Exit (Short, 3 ATRs ) 6.9348
Upper Bollinger Band 6.8183
Lower Bollinger Band 5.8297
Percent B (%b) 0.96
BandWidth 15.632511
MACD Line 0.278
MACD Signal Line 0.2752
MACD Histogram 0.0028
Fundamentals Value
Market Cap 482.55 Million
Num Shares 71.2 Million
EPS -0.38
Price-to-Earnings (P/E) Ratio -17.84
Price-to-Sales 29.83
Price-to-Book 7.11
PEG Ratio -0.47
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.25
Resistance 3 (R3) 7.27 7.14 7.17
Resistance 2 (R2) 7.14 7.02 7.13 7.15
Resistance 1 (R1) 6.96 6.94 6.89 6.94 7.12
Pivot Point 6.82 6.82 6.79 6.81 6.82
Support 1 (S1) 6.64 6.70 6.58 6.62 6.44
Support 2 (S2) 6.51 6.63 6.50 6.41
Support 3 (S3) 6.33 6.51 6.39
Support 4 (S4) 6.31